AI in Precision Medicine Market to Reach USD 32,410 Million by 2033 | Strong 38.7% CAGR | North America Leads with 46% Share | Key Players: IBM, Microsoft, NVIDIA, Illumina, AstraZeneca

AI in Precision Medicine Market Size and Outlook

The global AI in Precision Medicine Market reached US$ 1,703.19 million in 2024 and is projected to reach US$ 32,410 million by 2033, growing at a robust CAGR of 38.7% during the forecast period 2025-2033. The market is experiencing rapid expansion as artificial intelligence (AI) technologies transform how patient data including genomic, environmental, lifestyle, and clinical information is analyzed to enable personalized and predictive healthcare solutions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/ai-in-precision-medicine-market?Juli

AI in precision medicine utilizes advanced algorithms and machine learning models to interpret vast and complex datasets, supporting accurate disease diagnosis, biomarker identification, and individualized treatment planning. This paradigm shift is driven by the rising demand for tailored therapies, the increasing prevalence of chronic and life-threatening diseases, and accelerating advancements in genomics, proteomics, and multi-omics research. The market is also benefiting from strategic collaborations between AI developers, pharmaceutical firms, and healthcare providers aimed at integrating real-world evidence (RWE) into drug discovery, clinical trial optimization, and patient stratification. These partnerships are enhancing efficiency, reducing development costs, and enabling faster delivery of precision therapies.

Recent Developments:

✅ November 2025: Tempus Labs launched an AI-driven precision oncology platform that integrates genomic sequencing data with electronic health records (EHRs) to optimize personalized cancer treatment selection and improve clinical trial matching.

✅ September 2025: IBM Watson Health partnered with AstraZeneca to develop an AI-powered biomarker discovery platform leveraging multi-omics data to accelerate targeted drug development for oncology and rare diseases.

✅ June 2025: NVIDIA introduced an upgraded version of its Clara BioNeMo AI framework, designed to enhance genomic and proteomic data analysis for pharmaceutical R&D and precision diagnostics.

✅ April 2025: Microsoft and Roche expanded their collaboration to integrate cloud-based AI analytics for large-scale genomic data processing, improving diagnostic accuracy and real-time patient insights across oncology and neurology applications.

✅ February 2025: Google DeepMind unveiled a new AI model capable of predicting disease risk from whole-genome sequences, marking a major advance in predictive analytics and personalized treatment planning.

✅ January 2025: Illumina Inc. partnered with Amazon Web Services (AWS) to enhance AI-enabled genomic analysis pipelines, enabling faster data interpretation for precision oncology and genetic disease diagnostics.

✅ November 2024: Philips Healthcare launched an AI-powered precision cardiology platform integrating imaging data, genomics, and clinical insights to personalize cardiovascular disease prevention and management.

Mergers & Acquisitions:

✅ October 2025: Roche Holding AG acquired PathAI, a leader in AI-powered digital pathology, to strengthen its capabilities in precision oncology and accelerate integration of machine learning in diagnostic workflows.

✅ August 2025: Illumina Inc. acquired SOPHiA GENETICS' AI analytics division, enhancing its cloud-based genomic interpretation capabilities and expanding access to global clinical datasets for precision medicine applications.

✅ June 2025: NVIDIA Corporation completed the acquisition of Recursion Pharmaceuticals, combining AI-based drug discovery with high-performance computing to accelerate precision drug development.

✅ April 2025: Tempus Labs acquired Guardant Health's bioinformatics division, integrating advanced liquid biopsy analytics with AI-driven predictive models for cancer treatment optimization.

✅ February 2025: Oracle Health completed its acquisition of Owkin, a French AI biotech company, to expand its presence in real-world evidence generation and personalized therapeutic insights.

✅ December 2024: IQVIA Holdings Inc. acquired Genomenon, a genomics-based AI company, strengthening its clinical trial data curation and molecular diagnostics capabilities.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=ai-in-precision-medicine-market?Juli

Key Players:
IBM Corporation | Microsoft Corporation | AstraZeneca | Sanofi | GE Healthcare | Intel Corporation | NVIDIA Corporation | Alphabet Inc. | BioXcel Therapeutics Inc. | Enlitic Inc. | Google Inc. | Illumina Inc.

Key Highlights:

IBM Corporation - Holds a 12% share, leading through its Watson Health AI platform, which integrates data analytics, imaging, and clinical decision support for oncology and genomic medicine.

Microsoft Corporation - Holds a 10% share, driven by its Azure AI healthcare ecosystem and partnerships with pharmaceutical companies for cloud-based precision medicine and multi-omics data integration.

AstraZeneca - Holds a 9% share, leveraging AI for biomarker discovery, drug design, and patient stratification, with significant collaborations in oncology and immunology.

Sanofi - Holds an 8% share, investing in AI-driven digital biomarker programs and predictive modeling to enhance R&D productivity and targeted therapeutics.

GE Healthcare - Holds a 9% share, focusing on AI-based imaging and diagnostics solutions that integrate genomic data for precision oncology and radiogenomics applications.

Intel Corporation - Holds a 7% share, supporting high-performance AI computing infrastructure for genomics, predictive modeling, and large-scale biomedical data processing.

NVIDIA Corporation - Holds an 8% share, with its Clara BioNeMo and DGX AI platforms powering multi-omics analysis, imaging diagnostics, and AI-enabled drug discovery.

Alphabet Inc. (Google & DeepMind) - Combined 10% share, driving innovations in AI genomics, predictive analytics, and early disease detection models through Google Health and DeepMind initiatives.

BioXcel Therapeutics Inc. - Holds a 5% share, pioneering AI-guided drug repurposing and neuropsychiatric therapy development, accelerating precision drug identification.

Enlitic Inc. - Holds a 4% share, specializing in AI-enabled medical imaging interpretation and integration of radiomic data into personalized treatment workflows.

Illumina Inc. - Holds a 8% share, leading in AI-powered genomic sequencing and analytics, enabling faster interpretation of multi-omics data for personalized medicine.

Market Segmentation:

➥ By Technology, Machine Learning (ML) dominates with a 45% share, driven by its widespread use in predictive modeling, drug discovery, and patient outcome analysis. Natural Language Processing (NLP) holds 20%, enabling interpretation of unstructured clinical and genomic data from electronic health records (EHRs). Computer Vision accounts for 15%, primarily used in medical imaging, pathology, and radiogenomics. Deep Learning contributes 12%, powering advanced diagnostic tools and multi-omics data integration, while Others represent 8%, including reinforcement learning and hybrid AI models applied in clinical decision support systems.

➥ By Component, Software Solutions lead with a 52% share, encompassing AI platforms for genomic data interpretation, diagnostic modeling, and drug discovery automation. Hardware holds 30%, driven by increasing adoption of GPUs, AI chips, and high-performance computing infrastructure used for large-scale biomedical data analysis. Services account for 18%, including consulting, system integration, and cloud-based AI deployment services provided by healthcare technology companies.

➥ By Application, Oncology dominates with a 40% share, as AI-driven precision medicine solutions are widely applied in cancer diagnostics, biomarker identification, and personalized therapy planning. Cardiology holds 15%, supported by the growing use of AI tools for risk assessment, imaging, and precision interventions. Neurology contributes 12%, focusing on neurodegenerative diseases and psychiatric disorders. Immunology and Infectious Diseases account for 10%, integrating AI in vaccine development and immune response modeling. Pharmacogenomics and Drug Discovery represent 13%, while Others make up 10%, including metabolic, respiratory, and rare disease applications.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/ai-in-precision-medicine-market?Juli

Market Dynamics:

Driver: Advancements in AI Technologies
Rapid advancements in artificial intelligence technologies are a key driver of growth in the global AI in precision medicine market, transforming how patient data is analyzed, interpreted, and applied to deliver personalized healthcare solutions. Modern AI systems, including machine learning (ML), deep learning (DL), and natural language processing (NLP), enable the processing of massive datasets from genomics, proteomics, imaging, and electronic health records (EHRs) with remarkable speed and accuracy.

These innovations are accelerating biomarker identification, disease risk prediction, and individualized treatment design, moving healthcare beyond traditional one-size-fits-all approaches. Emerging tools such as generative AI, digital pathology, and continuous learning systems are streamlining clinical workflows, improving diagnostic precision, and shortening drug discovery timelines. AI-powered systems can now deliver biomarker analyses within minutes, assist in early cancer detection by interpreting imaging scans, and predict protein structures critical for targeted therapy development.

For instance, in March 2025, Google introduced TxGemma, a suite of open AI models based on DeepMind's Gemma architecture, designed to accelerate drug discovery and therapeutic development by integrating language understanding with chemical and protein structure prediction. Similarly, in January 2024, Siemens Healthineers collaborated with the Indian Institute of Science (IISc) to establish an AI laboratory in Bengaluru focused on neurology research, developing open-source AI tools for automated segmentation and analysis of neuroimaging data. Collectively, these advancements are driving greater accuracy, cost-efficiency, and speed across precision medicine applications, propelling market expansion globally.

Restraint: Data Privacy and Security Concerns
While AI technologies are revolutionizing healthcare, data privacy and security concerns remain a significant restraint on market growth. AI systems require access to vast volumes of sensitive patient data to function effectively, raising questions about data ownership, control, and consent. Risks include re-identification of anonymized datasets, unauthorized data sharing, and breaches of confidentiality, all of which undermine patient trust and regulatory compliance.

Despite ongoing efforts to strengthen cybersecurity and anonymization standards, advanced AI algorithms have demonstrated the ability to reconstruct or trace individual identities from complex data, intensifying fears about misuse and inadequate safeguards. The global regulatory environment remains fragmented, with frameworks such as HIPAA and GDPR providing partial guidance but lagging behind technological advancements.

To address these challenges, stakeholders must implement robust data governance frameworks, adopt privacy-preserving AI techniques such as federated learning and homomorphic encryption, and ensure strict adherence to emerging global data protection standards. Failure to establish effective safeguards could lead to data breaches, erosion of public confidence, and slower adoption of AI-driven healthcare solutions, thereby constraining the full potential of the global AI in precision medicine market.

Regional Insights:

North America dominates the global AI in precision medicine market, accounting for approximately 46% of total revenue in 2025. The region's leadership is attributed to its strong AI research ecosystem, widespread adoption of advanced healthcare analytics, and high concentration of biotech and pharmaceutical companies investing in precision medicine. The United States holds the largest share, supported by initiatives such as the All of Us Research Program and significant investments in AI-driven genomics, drug discovery, and digital health platforms. Major players such as IBM, Microsoft, NVIDIA, and Illumina continue to expand AI-integrated precision medicine solutions through partnerships with hospitals, research centers, and life science companies.

Europe represents the second-largest market, holding around 28% of the global share. Countries such as Germany, the United Kingdom, France, and Switzerland are driving adoption through national genomics initiatives, AI healthcare funding, and robust clinical research networks. The European Commission's support for AI-driven healthcare innovation, along with collaborations between pharma and tech companies, is accelerating the implementation of personalized healthcare solutions across oncology, neurology, and cardiovascular disease management.

Asia Pacific is an emerging high-growth region, accounting for approximately 20% of the global market. Rapid advancements in AI infrastructure, growing investments in genomics and precision diagnostics, and supportive government policies are fueling market expansion in China, Japan, South Korea, and India. China leads the region with aggressive national AI strategies and large-scale healthcare digitization programs, while India is rapidly growing due to AI-based diagnostic startups and international research collaborations in genomics and drug development.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.